A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

This study assessed hesitancy of HPV vaccination, associated factors, and barriers to vaccination among youth girls in Ethiopia. Methods: An institutional-based cross-sectional study was conducted ...

The same mRNA technology behind COVID-19 vaccines is now being used in the fight against cancer, and the Markey Cancer Center ...

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

Dr Nur Adila Mokhtar, Consultant Clinical Oncologist at OncoCare Cancer Centre Malaysia, shares, “The HPV vaccine is ...

Like infectious diseases, cancer will not observe a moratorium, and a halt in government vaccine research funding will ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.